Virax Biolabs eliminates Nigel McCracken's COO role

Dr. Nigel McCracken is scheduled to leave employment on December 23, 2026, while remaining a director.

Rhea-AI Filing Summary

Virax Biolabs Group Limited (VRAX) is restructuring senior management, eliminating the standalone Chief Operating Officer role and appointing Clement Monteil Acting Chief Scientific Officer for an initial six-month term, effective October 5, 2026. The company says the restructuring is designed to reduce operating expenditure and prioritize ViraxImmune development.

Dr. Nigel McCracken, whose COO position was made redundant, began paid garden leave on October 5, 2026; his employment is scheduled to end December 23, 2026, and he will remain a director. He will receive a statutory redundancy payment of £3,379.50 plus a payment in lieu of the balance of his three-month contractual notice period. Dr. Monteil has served as Head of Research and Development since 2022.

Key Figures

Acting Chief Scientific Officer initial term: six months Statutory redundancy payment: £3,379.50 Contractual notice period: three months +1 more

4 metrics

Acting Chief Scientific Officer initial term six months Clement Monteil's appointment effective October 5, 2026

Statutory redundancy payment £3,379.50 Payment to Dr. Nigel McCracken

Contractual notice period three months Balance paid in lieu to Dr. Nigel McCracken

Employment termination date December 23, 2026 Dr. Nigel McCracken

Key Terms

paid garden leave, statutory redundancy payment, payment in lieu

3 terms

paid garden leave regulatory

"commenced paid garden leave on October 5, 2026"

statutory redundancy payment regulatory

"a statutory redundancy payment of £3,379.50"

payment in lieu financial

"a payment in lieu of the balance of his three-month contractual notice period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is VRAX's acting chief scientific officer, and how long is the appointment?

Clement Monteil was appointed Acting Chief Scientific Officer for an initial term of six months, effective October 5, 2026. He has served as the company's Head of Research and Development since 2022, overseeing research and development, quality and manufacturing operations.

What payments will VRAX make to Nigel McCracken when his COO role ends?

Dr. Nigel McCracken will receive a statutory redundancy payment of £3,379.50 and a payment in lieu of the balance of his three-month contractual notice period. He began paid garden leave on October 5, 2026, and his employment is scheduled to terminate effective December 23, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/09/2026 - 04:15 PM Accepted by SEC EDGAR 10/09/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-41440

Virax Biolabs Group Limited

(Registrant’s Name)

BioCity Glasgow

Bo'Ness Road Newhouse

Lanarkshire, ML1 5UH

United Kingdom

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

When used in this Form 6-K, unless otherwise indicated, the terms “the Company,” “Virax,” “we,” “us” and “our” refer to Virax Biolabs Group Limited. and its subsidiaries.

Departure of Chief Operating Officer; Appointment of Acting Chief Scientific Officer

Following a review of its operating model, Virax Biolabs Group Limited (the “Company”) is implementing a restructuring of its senior management structure designed to streamline the organization and reduce operating expenditure whilst simultaneously prioritizing ViraxImmune development. As part of this restructuring, the Company has decided to eliminate the standalone role of Chief Operating Officer (“COO”).

In connection with the restructuring, the Company informed Dr. Nigel McCracken, the Company’s COO, that his position has been made redundant. Dr. McCracken commenced paid garden leave on October 5, 2026, and his employment with the Company will terminate effective December 23, 2026. Dr. McCracken will continue to serve as a director of the Board of Directors of the Company.

In connection with his departure, Dr. McCracken will receive (i) a statutory redundancy payment of £3,379.50 and (ii) a payment in lieu of the balance of his three-month contractual notice period, in accordance with applicable U.K. law and the terms of his employment agreement.

On October 5, 2026, the Board appointed Clement Monteil as Acting Chief Scientific Officer for an initial term of six months, effective immediately.

Dr. Clement Monteil, has served as the Company's Head of Research and Development since 2022, where he oversees research and development, quality and manufacturing operations. Prior to joining the Company, from 2015 to 2022, Dr. Monteil served as a Senior Scientist and subsequently as Technical Manager at LumiraDx Ltd, a

point-of-care diagnostics company, where he led the new technology development team, and from 2013 to 2015 he was a Postdoctoral Scientist at University College Dublin. Dr. Monteil holds a Ph.D. in Chemistry from the University of Caen-Normandie and an M.Sc. in Organic Chemistry from Aix-Marseille University.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			VIRAX BIOLABS GROUP LIMITED
Date:	October 9, 2026	By:	/s/ James Foster
			James Foster, Chief Executive Officer